Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Galina Stetsenko

Dermatology Seattle, WA Medical Doctor

NPI 1881777316 CMS profile 900903

1959 Ne Pacific St, Bb1353, Box 356524, Seattle, WA 98195

Open in the dashboard

General payments

$4,911

203 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Galina Stetsenko of Seattle, WA is reported in the CMS Open Payments database as having received $4,911 across 203 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,708 116
2024 General $1,608 72
2023 General $359 12
2021 General $121 1
2019 General $115 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Galina Stetsenko
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Galina Stetsenko were reported at $2,708. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Galina Stetsenko Dermatology median Middle half National median
2019 $115 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $121 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $359 $607 $159–$1,674 $160
2024 $1,608 $751 $204–$1,903 $164
2025 $2,708 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $691 15 payments
  2. Incyte Corporation $638 29 payments
  3. Janssen Biotech, Inc. $586 30 payments
  4. AbbVie, Inc. $487 22 payments
  5. Regeneron Healthcare Solutions, Inc. $407 13 payments
  6. Arcutis Biotherapeutics, Inc. $361 19 payments
  7. E.R. Squibb & Sons, L.L.C. $332 13 payments
  8. Sun Pharmaceutical Industries Inc. $239 9 payments
  9. LEO Pharma Inc. $187 8 payments
  10. Galderma Laboratories, L.P. $182 9 payments
  11. Other $800 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,597 199 payments
  2. Education $314 4 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $686 17 payments
  2. OPZELURA $638 29 payments
  3. TREMFYA $586 30 payments
  4. SOTYKTU $332 13 payments
  5. Zoryve $321 17 payments
  6. DUPIXENT Immunology And Inflammation $248 7 payments
  7. RINVOQ $248 11 payments
  8. LIBTAYO $236 5 payments
  9. NEMLUVIO $167 8 payments
  10. LITFULO $135 7 payments
  11. Other $1,494 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

547

Median for Dermatology: 534

Drug cost

$50,238

Median for Dermatology: $67,151

Branded share of claims

4.6%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opzelura Ruxolitinib Phosphate Brand 12 $22,968
Fluorouracil Generic 100 $9,222
Clobetasol Propionate Generic 81 $6,078
Tacrolimus Generic 29 $3,087
Doxycycline Hyclate Generic 43 $1,973
Metronidazole Generic 24 $1,472
Clobetasol Emollient Clobetasol Propionate/Emoll Brand 13 $1,152
Triamcinolone Acetonide Generic 74 $943
Econazole Nitrate Generic 27 $878
Ketoconazole Generic 62 $696

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$105,360

Of which drugs: $10,298

Medicare patients

346

Average age 74

Services billed

1,665

190 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 53%
Arthritis 41%
Diabetes 16%
Atrial fibrillation 16%
Ischemic heart disease 14%
Osteoporosis 14%
Cancer 13%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 17 33 $10,244

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $201
  • Regeneron Healthcare Solutions, Inc. $43
$245 — —
OPZELURA
  • Incyte Corporation $217
$217 12 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $195
$195 — —
TREMFYA
  • Janssen Biotech, Inc. $144
$144 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $132
$132 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

203 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record